Urocor, Inc.

Theracel Corporation

American Biotechnology Company

Johns Hopkins University

Laboratory Corporation of America Holdings

University of Tulsa

Cytodiagnostics, Inc.

Robert W Veltri

Gang An

S Mark O'Hara

David Ralph

Kaveh Ashenayi

Gabor B Fodor

M Craig Miller

Michael P Bacus

Kawporn Sussangkarn

Alan W Partin

Jonathan I Epstein

Donald P Coffey

Ying Hu

Gerard J O'Dowd

Garry M Marley

Peter E Maxim

Disclosed are nucleic acid and amino acid sequences encoded by a novel, prostate specific gene (UC41) and diagnostic techniques for the detection of human prostate cancer utilizing such nucleic acid and amino acid sequences. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. Methods of treatment for prostate cancer utilizing antisense constructs or antibodies specific for UC41 gene products are also described.

Prostate-specific gene for diagnosis, prognosis and management of prostate cancer

Disclosed are diagnostic techniques for the detection of human disease states that affect gene expression in peripheral leukocytes. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in the peripheral blood of individuals with such a disease state compared to normal healthy individuals. The invention further relates to methods for detection of protein species that are differentially expressed in the peripheral blood of individuals with such a disease state compared to normal healthy individuals. Genetic probes, antibody probes and methods useful in monitoring the progression and diagnosis of two specific disease states, prostatic cancer and breast cancer, are described.

Diagnosis of disease state using mRNA profiles in peripheral leukocytes

A neural network is used in a system to detect abnormalities in cells, including cancer in bladder tissue cells. The system has an image analysis system for generating data representative of imaging variables from an image of stained cells. The set of data is provided to a neural network which has been trained to detect abnormalities from known tissue cells with respect to the data from the same set of imaging variables. A conventional sigmoid-activated neural network, or alternatively, a hybrid neural network having a combination of sigmoid, gaussian and sinusoidal activation functions may be utilized. The trained neural network applies a set of weight factors obtained during training to the data to classify the unknown tissue cell as normal or abnormal.

Neural network for cell image analysis for identification of abnormal cells

Disclosed are diagnostic techniques for the detection of human prostate, bladder and breast cancer. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate, bladder and breast cancer are described. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in prostate, bladder and breast cancer compared to normal human prostate, benign prostatic hyperplasia, or normal bladder or breast tissue.

Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer

Diagnosis of disease state using MRNA profiles in peripheral leukocytes

Prostate-specific gene for diagnosis, prognosis and management of

A method for screening individuals at risk for prostate cancer progression is disclosed. The method is useful for evaluating cells from patients at risk for recurrence of prostate cancer following surgery for prostate cancer. Specifically, the method uses specific Markovian nuclear texture factors, alone or in combination with other biomarkers, to determine whether the cancer will progress or lose organ confinement. In addition, methods of predicting the development of fatal metastatic disease by statistical analysis of selected biomarkers is also disclosed. The invention also contemplates a method that uses a neural network to analyze and interpret cell morphology data. Utilizing Markovian factors and other biomarkers as parameters, the network is first trained with a sets of cell data from known progressors and known non-progressors. The trained network is then used to predict prostate cancer progression in patient samples.

Prediction of prostate cancer progression by analysis of selected

A method for screening individuals at risk for the loss of organ confinement in prostate cancer is disclosed. The method is useful for evaluating cells from patients at risk for recurrence of prostate cancer following surgery for prostate cancer. Specifically, the method uses specific Markovian nuclear texture features, alone or in combination with other biomarkers, to determine whether the cancer will progress or lose organ confinement. In addition, methods of predicting the development of fatal metastatic disease by statistical analysis of selected biomarkers is also disclosed. The invention also contemplates a method that uses a neural network to analyze and interpret cell morphology data. Utilizing Markovian factors and other biomarkers as parameters, the network is first trained with a sets of cell data from known progressors and known non-progressors. The trained network is then used to predict the loss of organ confinement by evaluating patient samples.

Sextant core biopsy predictive mechanism for non-organ confined disease

Disclosed are diagnostic techniques for the detection of human prostate cancer. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in prostate cancer compared to normal human prostate or benign prostatic hyperplasia.

Biomarkers and targets for diagnosis, prognosis and management of

A method for selectively inducing expression of biomarkers for urologic cancers, including prostate and bladder cancer, is disclosed. Tumor cells are cultured using a low shear rotational three-dimensional technique under conditions effective to induce said selective expression. The method is useful for diagnostic and therapeutic applications.

Method for selectively inducing biomarker expression in urologic tumor

The compounds 2-(5-methylthiomethyl-2-furyl)-2-hydroxy-3-keto-4- dihydroxyethylbutyrolactone and 2-(5-methoxymethyl-2- furyl)-2-furyl(-2-hydroxy-3-keto-4-dihydroxyethylbutyrolactone and pharmaceutical compositions containing them are useful to regulate the immune response in mammals.

Pharmaceutically useful furyl substituted dihydroxyethylbutyrolactones

Michael addition products of ascorbic acid and selected unsaturated aldehydes and ketones are useful as immunomodulators in mammals.

Pharmaceutically useful Michael addition products of unsaturated

It has now been discovered that the acid catalyzed Michael reaction products of ascorbic acid and certain selected ketones are useful for their therapeutic activity. More specifically the useful reaction products of the invention are those obtained by reactions of ascorbic acid with .alpha.,.beta. unsaturated alicyclic diketones containing from 5 to 7 carbon atoms. The preferred compounds of the invention may be represented by the formula: ##STR1## wherein n is 1, 2 or 3. The ability of the compounds of this invention to stimulate an immune response has been established by a number of art recognized tests.

Condensation products of cyclic diketones and ascorbic acid as

Treatment of inflammation in mammals utilizing selected ketobutyrolactones and furylbutyrolactones. Treatment is applicable to both acute or chronic inflammation. Antiviral activity of methylfurylbutyrolactone is also disclosed.

Growing community of inventors

Oklahoma City, OK, United States of America

Robert W Veltri